
    
      This is a Phase 2/3, multi-center, randomized, double-masked, vehicle-controlled study to
      assess the efficacy and safety of three different concentrations of VOS when administered in
      both eyes (OU) twice a day (BID) over 12 weeks in subjects with mild to moderate DES.
      Subjects will undergo a 14- to 17-day run-in period in which VOS vehicle will be
      self-administered OU, BID. Subjects will be re-assessed to confirm they meet all of the
      inclusion criteria and none of the exclusion criteria. It is estimated that the study will
      enroll approximately 480 subjects across approximately 9 study centers. Eligible subjects
      will be randomized in a 1:1:1:1 ratio to one of the following study treatment groups after
      the 14- to 17-day run-in period.
    
  